Last updated: May 20, 2026
TREMFYA (guselkumab) Clinical Trials Update, Market Analysis, and Patent/Generic Outlook (2026)
TREMFYA (guselkumab) is a blockbuster IL-23p19 monoclonal antibody for plaque psoriasis. The core growth and revenue durability case rests on (1) continued uptake and persistence in moderate-to-severe plaque psoriasis, (2) expansion in additional immune-mediated diseases under development, and (3) barriers created by the branded clinical and safety package plus patent coverage that delays generic or biosimilar substitution in the US and key ex-US markets. The near-term investment and competitive focus remains on biosimilar entry risk, label expansion, payer restrictions, and ongoing Phase 3 readouts in new indications and regimens.
What clinical trials readouts are expected for TREMFYA (guselkumab) in 2025-2027?
Which late-stage studies drive the next label-expansion waves?
Key development themes for guselkumab include:
- broader dermatology indications beyond plaque psoriasis
- additional dosing/regimen evaluations
- head-to-head or active-comparator studies to support payer and formulary positioning
- longer-term outcomes for durability, safety, and treat-to-target endpoints
What endpoints matter for payers and regulators?
For IL-23p19 agents, market-shaping readouts typically emphasize:
- PASI 90/100 response rates and durability through maintenance intervals
- long-term safety (infection rates, malignancy signals, laboratory trends)
- functional outcomes when trials include comorbidities (fatigue, itch, quality of life)
- stopping/retreatment outcomes in maintenance frameworks
What is the practical update focus for 2026 planning?
For a commercial and licensing plan, the relevant “trial update” is less about early-phase novelty and more about whether new studies:
- extend the addressable patient population
- strengthen justification for step therapy and prior authorization criteria
- reduce payer uncertainty through longer follow-up and real-world comparability
How big is the TREMFYA market and what are the latest commercial benchmarks?
Where does revenue concentration sit?
Guselkumab revenue exposure concentrates in:
- the US biologics market for moderate-to-severe plaque psoriasis
- high tier payer segments where IL-23 therapy is favored over older systemic options
What drives unit growth vs price/mix?
Primary levers for TREMFYA’s market trajectory:
- ongoing patient acquisition in biologic-naïve and switched populations
- persistence and dose optimization versus intermittent biologic failure
- payer contracting strategy that protects share versus adalimumab biosimilars and other IL-17/IL-23 agents
- sequencing dynamics after biosimilar launches in the same class or adjacent MoAs
Market projections: base-case structure
A practical projection model for TREMFYA in 2026 uses:
- expected erosion from biosimilar entry risk (class-level and molecule-level)
- label expansion contribution (if positive late-stage outcomes translate to approvals)
- competitive share movement due to head-to-head perceptions and formulary placement
- pricing and rebate evolution tied to category competition
When does TREMFYA lose exclusivity in the US, and what does that mean for biosimilar entry risk?
Patent and exclusivity mechanics that govern guselkumab
For a biologic like TREMFYA, exclusivity and patent expiry are not the same as small-molecule “generic” timing. The relevant gating items for follow-on competition are:
- composition-of-matter and formulation method patents
- manufacturing process patents
- use and treatment regimen patents
- US biologics exclusivity (12 years from first FDA approval for brand-new biologics, then patent expiration determines follow-on timing)
- biosimilar and interchangeable exclusivity outcomes depend on reference product designation and patent litigation outcomes
What is the risk window for biosimilars?
Commercially, biosimilar timelines are assessed as:
- the earliest lawful BLA submission timing relative to FDA reference product rules
- the earliest commercial launch after patent expiry and any settlement triggers
- the scope of any court rulings that carve out or invalidate asserted claims
What determines whether a biosimilar can launch quickly?
Launch pace depends on:
- whether asserted patents are stayed, narrowed, or invalidated
- whether there are settlement agreements limiting launch dates or claim design-arounds
- whether the biosimilar sponsors must modify manufacturing or analytical similarity to navigate enforceable claims
What patents protect TREMFYA (guselkumab), and how strong is the patent estate?
How patent estates typically split for guselkumab
For IL-23p19 antibodies, enforcement often spans:
- antibody composition and variants (including specific epitopes/sequence-defined claims)
- pharmaceutical formulations (stabilizers, buffers, freeze-thaw stable compositions)
- methods of treatment (specific dosing schedules or patient subgroups)
- manufacturing and purification processes
How to assess patent “strength” for business decisions
A defensible “strength” metric is based on:
- the number of active, asserted patents in the US per jurisdiction
- claim scope breadth and claim construction history in related litigation
- whether key claims are composition-centric or more easily designed around
- how close key claims sit to expiry relative to biosimilar submission cycles
What is the Orange Book status of TREMFYA (guselkumab) and is it relevant for biosimilars?
Orange Book vs Purple Book
TREMFYA is a biologic; its relevant listing is typically in the FDA’s biologics-specific infrastructure rather than the Orange Book’s small-molecule framework.
- The Orange Book is for approved drugs including many small molecules.
- Biosimilar and reference product status tracking is handled through biologics-specific records (often “Purple Book” in common practice).
Business takeaway
The Orange Book is usually not the primary tool for guselkumab follow-on planning. The practical planning artifact is:
- patent lists and FDA reference product designations tied to biosimilar licensure pathways
- the court docket and settlement terms tied to specific patents
Which companies are developing guselkumab biosimilars, and what are the launch timelines under Paragraph IV-style challenges?
How US biosimilar challenges differ from Hatch-Waxman Paragraph IV
Biosimilar challenge mechanics follow the biosimilar approval pathway under the BPCIA framework, not the Orange Book Paragraph IV label used for small molecules. Still, the practical commercial outcome is similar:
- a manufacturer challenges reference product exclusivity and/or asserted patents
- litigation determines whether launch is blocked or limited
What matters for market forecasting
Forecasting for guselkumab biosimilar competition depends on:
- which applicants have active litigation with the reference sponsor
- the status of any district court decisions and Federal Circuit appeals
- potential settlement agreements that lock in a controlled launch date
What generic or biosimilar entry risks exist for TREMFYA, and where are they concentrated geographically?
US vs ex-US timing
Commercial risk differs by region due to:
- differences in patent term adjustments
- differences in enforcement intensity and litigation speed
- differences in regulatory approval timelines for biosimilars
Europe and UK considerations
For the EU/UK, planning focuses on:
- EMA biosimilar extrapolation decisions by indication
- patent enforcement in EU member states where distribution occurs
- tender dynamics in national health systems and pharmacy benefit design
How does TREMFYA (guselkumab) compare with IL-17 and other IL-23 therapies on efficacy and competitive positioning?
Comparative market framing
TREMFYA competes against:
- IL-17 pathway therapies where PASI and nail outcomes are key formulary drivers
- other IL-23p19 therapies where head-to-head or network meta-analysis outcomes are used in payer criteria
What drives switching
Switching to or from guselkumab depends on:
- response speed and durability
- injection convenience, tolerability, and comorbidity fit
- payer step-therapy rules and prior authorization criteria
- patient-specific history including prior biologic failures
What formulations and delivery systems are protected for TREMFYA, and do they constrain biosimilar manufacturing?
Formulation and stability as enforceable barriers
For antibodies, biosimilar sponsors may face patent risk around:
- specific excipient systems and buffers
- stability requirements that preserve potency across shelf life
- manufacturing parameters that achieve comparable critical quality attributes
How manufacturing patents influence design-around strategies
Even when sequence claims are navigated, manufacturing process claims can:
- impose additional validation steps
- limit the ability to run identical upstream/downstream workflows
- create enforceable risk that slows launch readiness
What TREMFYA patent litigation affects biosimilar entry, and what are the settlement outcomes?
Litigation mapping used in commercial planning
For a launch-risk model, the litigation map is structured as:
- asserted patents by number and claim type (composition, method, formulation, process)
- current procedural posture (dismissal, infringement findings, appeal)
- any preliminary injunction motions and stays
- settlement agreements specifying effective launch dates or covenants
Settlement terms that matter
Market projections should incorporate:
- “no launch until” dates
- licensed entry scopes (some settlements allow limited early commercialization)
- royalty or cost-sharing agreements that affect net revenue even after launch
What is the FDA regulatory status of TREMFYA, and what label expansions have already occurred?
Regulatory basis for market durability
Guselkumab’s clinical and regulatory record supports:
- durable PASI responses in long-term maintenance frameworks
- safety profile acceptance for chronic use populations
- label breadth that supports multi-segment payer adoption
How to interpret “label expansion” for revenue forecasting
Revenue impact comes only when:
- approval expands the treatable population measurably
- payers update coverage criteria to include the new indication
- providers adopt the therapy earlier in treatment sequences
What is the commercial projection for TREMFYA through 2028 under base-case, downside, and upside scenarios?
Scenario framework
Three inputs define the projection range:
- biosimilar competition timing and intensity
- persistence and switching dynamics within plaque psoriasis
- incremental contribution from any new approved indications or regimen improvements
Base-case
- continued share protection through maintenance and payer contracting strength
- gradual competitive pressure from IL-17 and other IL-23 competitors
- biosimilar entry, if delayed by patent or litigation posture, is limited in timing within the forecast horizon
Downside
- earlier-than-modeled biosimilar access or stronger-than-modeled competitive pricing pressure
- faster payer churn toward lower-net-price alternatives
- weaker persistence due to switching caused by adverse outcomes or perceived comparative effectiveness
Upside
- successful late-stage readouts leading to prompt label expansions
- improved contracting economics (lower rebate burden via outcomes-based frameworks)
- persistence improvement via real-world adherence and patient satisfaction
Which patent and biosimilar strategy would most reduce TREMFYA revenue erosion risk?
Highest-impact levers
- tighten defensible claim coverage in remaining jurisdictions through continued enforcement where permitted
- use litigation posture and any settlement terms to manage launch timing risk
- align commercial access strategy with payer criteria that track clinical endpoints in the latest evidence
- prioritize evidence generation for durability and long-term safety to limit payer willingness to switch
Key Takeaways
- TREMFYA’s next commercial leg depends on durability/persistence in plaque psoriasis and whether late-stage guselkumab programs add meaningful new label or regimen value.
- Biosimilar competition timing is the dominant driver of downside risk, governed by the patent estate, US regulatory reference product rules, and litigation or settlement outcomes.
- Forecasting requires scenario modeling around (1) biosimilar launch timing and intensity, (2) payer contracting dynamics, and (3) persistence and switching patterns.
- Formulation and manufacturing barriers can matter even when sequence claims are navigated, affecting biosimilar readiness and enforceable design-around options.
FAQs
- What milestones in guselkumab clinical development typically change payer coverage decisions fastest?
- How do biosimilar litigation and settlement terms for biologics usually translate into revenue impact for the reference product?
- What factors most influence whether an IL-23 therapy maintains formulary preference after biosimilar launches in the class?
- How do manufacturing-process patents affect the feasibility and timing of guselkumab biosimilar launches?
- What comparative endpoints for plaque psoriasis most predict switching from guselkumab to competing IL-17 or IL-23 therapies?
References
- FDA. BPCIA biologics guidance and biosimilar regulatory framework. U.S. Food and Drug Administration. (Accessed 2026-05-20).
- FDA. Drugs@FDA database entry for TREMFYA (guselkumab). U.S. Food and Drug Administration. (Accessed 2026-05-20).
- FDA. Orange Book and biologics/patent listing resources. U.S. Food and Drug Administration. (Accessed 2026-05-20).
- EMA. Assessment framework for biosimilars and extrapolation. European Medicines Agency. (Accessed 2026-05-20).
